Hanmi Pharmaceutical's stock plummets 14% due to poor performance in China
Hanmi Pharmaceutical's stock price fell sharply on the 29th due to the spotlight on the poor performance of its Chinese subsidiary in the second quarter, leading to downward revisions in target prices by securities firms. The stock closed at 322,000 won, down 14.02% from the previous trading day. While overall performance improved, market attention focused on the Chinese business, where Beijing Hanmi Pharmaceutical's second-quarter operating profit was only 600 million won, a 96.6% decrease year-on-year.
How this call is verified
The ▼ Bearish call is auto-verified against the actual BTC price in ~23h.
Bar: BTC ±1% within 24h · every verdict lands on the public ledger
Key takeaway
"Hanmi Pharmaceutical's stock plummets 14% due to poor performance in China" — BullBear's AI rates this story as a bearish (negative) signal for markets, with a market-impact score of 60 out of 100. Hanmi Pharmaceutical's stock price fell sharply on the 29th due to the spotlight on the poor performance of its Chinese subsidiary in the second quarter, leading to downward revisions in target prices by securities firms. The stock closed at 322,000 won, down 14.02% from the previous trading day. While overall performance improved, market attention focused on the Chinese business, where Beijing Hanmi Pharmaceutical's second-quarter operating profit was only 600 million won, a 96.6% decrease year-on-year. Reported by TokenPost on July 29, 2026. The call is verified against the actual 24-hour price move on BullBear's public conviction ledger.
Catch the next bear flag
Telegram alerts when our AI scores a story 80+/100 impact (~1-3 per day, no spam). Verified 30d hit rate 50.8%.